Amb motiu del tancament d'estiu, la validació de documents es reprendrà a partir del 28 d'agost de 2026. Disculpeu les molèsties.
Con motivo del cierre de verano, la validación de documentos se reanudará a partir del 28 de agosto de 2026. Disculpad las molestias
Due to the summer closure, document validation will resume starting August 28, 2026. We apologize for any inconvenience.

Characterization of Plasminogen Binding to NB4 Promyelocytic Cells Using Monoclonal Antibodies against Receptor-Induced Binding Sites in Cell-Bound Plasminogen

dc.contributor.authorJardí Ripoll, Mercè
dc.contributor.authorFàbregas, Pere
dc.contributor.authorSagarra Tió, María
dc.contributor.authorPérez Lucena, María José
dc.contributor.authorFélez, Jordi
dc.date.accessioned2018-11-29T09:15:54Z
dc.date.available2018-11-29T09:15:54Z
dc.date.issued2012
dc.date.updated2018-07-24T12:57:05Z
dc.description.abstractThe NB4 promyelocytic cell line exhibits many of the characteristics of acute promyelocytic leukemia blast cells, including the translocation (15 : 17) that fuses the PML gene on chromosome 15 to the RAR alpha gene on chromosome 17. These cells have a very high fibrinolytic capacity. In addition to a high secretion of urokinase, NB4 cells exhibit a 10-fold higher plasminogen binding capacity compared with other leukemic cell lines. When tissue-type plasminogen activator was added to acid-treated cells, plasmin generation was 20-26-fold higher than that generated by U937 cells or peripheral blood neutrophils, respectively. We found that plasminogen bound to these cells can be detected by fluorescence-activated cell sorting using an antiplasminogen monoclonal antibody that specifically reacts with this antigen when it is bound to cell surfaces. All-trans retinoid acid treatment of NB4 cells markedly decreased the binding of this monoclonal antibody. This cell line constitutes a unique model to explore plasminogen binding and activation on cell surfaces that can be modulated by all-trans retinoid acid treatment.
dc.format.extent7 p.
dc.format.mimetypeapplication/pdf
dc.identifier.pmid23118518
dc.identifier.urihttps://hdl.handle.net/2445/126561
dc.language.isoeng
dc.publisherHindawi Publishing Corporation
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1155/2012/984589
dc.relation.ispartofJournal of Biomedicine and Biotechnology, 2012, vol. 2012
dc.relation.urihttps://doi.org/10.1155/2012/984589
dc.rightscc by (c) Jardí et al., 2012
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.sourceArticles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
dc.subject.classificationLeucèmia
dc.subject.classificationCromosomes humans
dc.subject.otherLeukemia
dc.subject.otherHuman chromosomes
dc.titleCharacterization of Plasminogen Binding to NB4 Promyelocytic Cells Using Monoclonal Antibodies against Receptor-Induced Binding Sites in Cell-Bound Plasminogen
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
JardiM.pdf
Mida:
1.12 MB
Format:
Adobe Portable Document Format